2018
DOI: 10.1016/j.jcin.2017.10.023
|View full text |Cite
|
Sign up to set email alerts
|

Randomized Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusions

Abstract: As compared with wire escalation, upfront use of the CrossBoss catheter for antegrade crossing of coronary chronic total occlusions was associated with similar crossing time, similar success and complication rates, and similar equipment use and cost.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
19
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
2

Relationship

4
5

Authors

Journals

citations
Cited by 49 publications
(19 citation statements)
references
References 22 publications
0
19
0
Order By: Relevance
“…The CrossBoss First trial was a multicenter, randomized-controlled trial that compared upfront use of the CrossBoss microcatheter (Boston Scientific) versus standard wire escalation for antegrade CTO crossing. 5 This study included 246 patients and showed no difference in procedural success, procedure time or equipment cost suggesting that either approach is reasonable. Werner et al performed a randomized trial in 396 patients to assess symptomatic improvement with CTO PCI.…”
Section: Chronic Total Occlusionsmentioning
confidence: 82%
“…The CrossBoss First trial was a multicenter, randomized-controlled trial that compared upfront use of the CrossBoss microcatheter (Boston Scientific) versus standard wire escalation for antegrade CTO crossing. 5 This study included 246 patients and showed no difference in procedural success, procedure time or equipment cost suggesting that either approach is reasonable. Werner et al performed a randomized trial in 396 patients to assess symptomatic improvement with CTO PCI.…”
Section: Chronic Total Occlusionsmentioning
confidence: 82%
“…The CrossBoss First trial compared upfront use of the CrossBoss catheter with AWE for CTO crossing. 88 It demonstrated similar crossing time, success and complication rates, and costs, suggesting that both strategies are acceptable as an initial approach. Crossing time was shorter with upfront use of the CrossBoss catheter in in-stent restenotic lesions.…”
Section: Use Of Dissection/reentry Strategiesmentioning
confidence: 85%
“…The solution depends on whether the caps are within, proximal, or distal to the stent, as shown. For lesions with both caps contained in the stent, a CrossBoss (Boston Scientific) is an excellent initial strategy as it will likely cross the distal cap in‐stent . If the CrossBoss will not advance through the stented segment (often due to a stent strut or edge), it can be wire‐redirected into the CTO body.…”
Section: In‐stent Cto Algorithmmentioning
confidence: 99%